The premise of tumor immunotherapy is that tumor cells can be eliminated by host cytotoxic CD8+ T cells, and these cells themselves can be affected by regulatory T (Treg) cells, induced expression of programmed death-1 (PD-1) and other inhibitory checkpoint receptors, which limit the antitumor function of cytotoxic lymphocytes [119]. This evidence concerns the gene CD8A and neoplasm.